SalHead: Salivary Inflammatory Markers in Tension Type Headache and Migraine

Sponsor
National and Kapodistrian University of Athens (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03727672
Collaborator
(none)
90
1
60
1.5

Study Details

Study Description

Brief Summary

Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age matched healthy controls . Τhe investigators, also investigated whether these markers could be influenced by comorbidities such as depression and anxiety.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Sixty subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of University Hospital of Athens between January to March 2016. 30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives.

    Initially, the participants completed the Hamilton Anxiety (HAM-A), Scale Beck Depression Inventory (BDI). All patients had to keep a headache diary during the four-week run-in period. All headache suffers were instructed to collected salivary headache-free baseline samples at the time of study screening when they had been free of headache for at least 48 hours (time point A). All headache suffers collected additional samples during moderate/severe headache (time point B), and at self-defined resolution phase 24 hours of their headache attack (time point C). Healthy control subjects were instructed to collected samples at the time of study screening (time point D). Every week, until four weeks and one month after the end of the study, participants were contacted, in order to ensure the compliance and the appropriate use of the technique. One year later longitudinal data would also be obtain.

    Saliva Sample Collection Detailed instructions for the correct collection of saliva samples were given to all participants. Such instructions include avoiding eating a major meal and teeth brushing 60 minutes prior to sample collection. Also consumption of high sugar and caffeine content foods as well as high acidity foods have to be excluded before saliva sample collection. Mouth rinse with water in order to remove any food residue and saliva sample collection at least 10 minutes after mouth rinse was recommended. Unstimulated whole saliva that pooled on the mouth floor were collected from patients and healthy volunteers in high quality polypropylene vials by the passive drool technique. Finally, all samples were stored in a plastic container at 2-4 ° C until analysis. Saliva was collected from the participants, at 8.00 a.m. in the morning in order to rule out any confounding factor caused by circadian rhythm.

    Sample Analysis Morning samples were kept in the refrigerator at 4°C and at the end of the day were brought to the laboratory where they were centrifuged 3000 rpm at 4°C and the supernatant was aliquoted in to polypropylene Cryogenic vials. Vials were frozen in -80°C until analyzed. Saliva transferrin levels were measured by competitive immunoassay kits and Interleukin-6, Interleukin-1β and CRP levels were measured by sandwich ELISA kits. Transferrin levels were used as a screening tool for the presence of blood in saliva samples and samples with transferrin values greater than 1 mg/dl were considered as candidates for exclusion in other salivary assays. Cortisol assay has a sensitivity of < 0.007 μg/ml and an inter-assay coefficient of variation of < 11% while these characteristics are 0.07 pg/ml and 8 for Interleukin-6, 0.37 pg/ml and 7 for Interleukin-1β, 10 pg/ml and 11.2 for CRP as well as 0.08 mg/dl and 7.2 for transferrin respectively.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    90 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Salivary Inflammatory Markers (Interleukin -1β, Interleukin -6, C- Reactive Protein) in Tension Type Headache and Migraine
    Actual Study Start Date :
    Jan 1, 2016
    Anticipated Primary Completion Date :
    Dec 30, 2020
    Anticipated Study Completion Date :
    Dec 30, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Tension type headache patients

    30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.

    Migraine patients

    30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.

    age matched controls

    30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives

    Outcome Measures

    Primary Outcome Measures

    1. migraine/Tension type Headache and C reactive protein [2 years]

      establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of C reactive protein

    2. migraine/Tension type Headache and Interleukin -1β [2 years]

      establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-1β

    3. migraine/Tension type Headache and Interleukin-6 levels [2 years]

      establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-6 levels

    Secondary Outcome Measures

    1. C reactive protein concentrations [2 years]

      C reactive protein concentrations as assessed using sandwich ELISA kits

    2. Interleukin-1β concentrations [2 years]

      Interleukin-1β concentrations as assessed using sandwich ELISA kits

    3. Interleukin-6 levels concentrations [2,5 years]

      Interleukin-6 levels concentrations as assessed using sandwich ELISA kits

    4. Anxiety [2,5 years]

      Anxiety as assessed using the Hamilton Anxiety (HAM-A)

    5. Depression [2,5 years]

      Depression as assessed using the Beck Depression Inventory (BDI)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • aged from 18 to 60 years old

    • Tension type Headache (TTH) and migraine, fulfilling the criteria International Classification of Headache Disorders, 3rd edition (beta version)

    Exclusion Criteria:
    • abnormal plasma CRP, Interleukin-1β and Interleukin-6 levels (>10 mg/L)

    • smoking cigarettes > 1 pack/day;

    • current pregnancy, lactation, or hormonal contraceptive use

    • alcohol or substance abuse

    • drug use such as anticoagulants, statins, or hormonal drugs

    • anti-inflammatory therapy

    • other primary or secondary headaches

    • major psychiatric disease

    • oral health problems.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Eginition Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece Athens Greece 11528

    Sponsors and Collaborators

    • National and Kapodistrian University of Athens

    Investigators

    • Principal Investigator: ANASTASIA BOUGEA, PHD, National and Kapodistrian University of Athens

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anastasia Bougea, Clinical Researcher, National and Kapodistrian University of Athens
    ClinicalTrials.gov Identifier:
    NCT03727672
    Other Study ID Numbers:
    • 638/5.11.2015
    First Posted:
    Nov 1, 2018
    Last Update Posted:
    Sep 10, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Anastasia Bougea, Clinical Researcher, National and Kapodistrian University of Athens
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 10, 2020